RecruitingPHASE1, PHASE2NCT05395624

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ashvattha Therapeutics, Inc.
Principal Investigator
Farshad Moradi, MD
Stanford University
Intervention
18F-OP-801(drug)
Enrollment
65 enrolled
Eligibility
18-80 years · All sexes
Timeline
20232026

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05395624 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials